William Blair analyst Matt Phipps has maintained their bullish stance on CNTX stock, giving a Buy rating on October 27.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matt Phipps’s rating is based on several promising developments within Context Therapeutics. The company recently shared preliminary data from its Phase Ia study of the CLDN6xCD3 T-cell engager, CTIM-76, which showed early signs of antitumor activity. Notably, a patient with platinum-resistant ovarian cancer demonstrated a RECIST response, indicating potential effectiveness of the treatment.
Additionally, the ongoing study has not encountered any severe cytokine release syndrome events or dose-limiting toxicities, suggesting a favorable safety profile. The absence of a maximum tolerated dose being reached further supports the potential for continued dose escalation. These factors collectively contribute to the positive outlook for Context Therapeutics, justifying the Buy rating.
In another report released on October 27, Piper Sandler also maintained a Buy rating on the stock with a $4.00 price target.